Scholarlink

Introduction <p>Preoperative anemia (PA) and red blood cell transfusion (RBT) are associated with decreased survival in several cancers. In muscle-invasive bladder cancer (MIBC), anemia is frequent and may be worsened by neoadjuvant chemotherapy (NAC). While PA’s impact is known in patients undergoing cystectomy without NAC, its prognostic value in the current multimodal approach remains unclear.</p> Methods <p>We retrospectively analyzed patients with cT2–T4 N0–N2 M0 MIBC treated with cisplatin-based NAC followed by radical cystectomy and lymphadenectomy between 2011 and 2022. We recorded the lowest hemoglobin value from NAC start to surgery (PA), use of RBT during NAC, and iron or vitamin B9/B12 supplementation.</p> Results <p>This monocentric cohort included 175 patients (77% men, median age 65); 79% received dose-dense-MVAC, 75% had ≥ 4 cycles, median follow-up was 59 months. PA was present in 95%, with 58.2% having grade &gt; 1. Among these, 50% received ≥ 1 transfusion, and 34.7% received supplementation. PA grade &gt; 1 was significantly associated with worse OS (HR = 2.67, <i>p</i> = 0.006), RFS (HR = 2.00, <i>p</i> = 0.019), and SS (HR = 3.35, <i>p</i> = 0.003) versus PA grade 0–1. Other independent prognostic factors for OS included neutrophil count &gt; 7 G/L (HR = 2.71, <i>p</i> = 0.010) and ypN+ (HR = 10.35, <i>p</i> &lt; 0.001). RBT had no significant impact.</p> Conclusion <p>This retrospective analysis demonstrated that PA grade &gt; 1 negatively impacts overall survival, independent of other prognostic factors, in patients with MIBC treated with NAC. However, it remains necessary to determine whether — and how — optimizing hemoglobin levels before cystectomy could improve outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy

  • 期刊论文

  • 发表日期：

    2026年5月14日

查看全文
  • Elsa Lafitte,
  • Patrick Sfumato,
  • Jochen Walz,
  • Emilien Billon,
  • Nicolas Branger,
  • Cécile Vicier,
  • Stanislas Rybikowski,
  • Mathilde Guérin,
  • Thomas Maubon,
  • Mathilde Beaufils,
  • Lorène Seguin,
  • Naji Salem,
  • Serge Brunelle,
  • Géraldine Pignot,
  • Gwenaelle Gravis

摘要

Introduction

Preoperative anemia (PA) and red blood cell transfusion (RBT) are associated with decreased survival in several cancers. In muscle-invasive bladder cancer (MIBC), anemia is frequent and may be worsened by neoadjuvant chemotherapy (NAC). While PA’s impact is known in patients undergoing cystectomy without NAC, its prognostic value in the current multimodal approach remains unclear.

Methods

We retrospectively analyzed patients with cT2–T4 N0–N2 M0 MIBC treated with cisplatin-based NAC followed by radical cystectomy and lymphadenectomy between 2011 and 2022. We recorded the lowest hemoglobin value from NAC start to surgery (PA), use of RBT during NAC, and iron or vitamin B9/B12 supplementation.

Results

This monocentric cohort included 175 patients (77% men, median age 65); 79% received dose-dense-MVAC, 75% had ≥ 4 cycles, median follow-up was 59 months. PA was present in 95%, with 58.2% having grade > 1. Among these, 50% received ≥ 1 transfusion, and 34.7% received supplementation. PA grade > 1 was significantly associated with worse OS (HR = 2.67, p = 0.006), RFS (HR = 2.00, p = 0.019), and SS (HR = 3.35, p = 0.003) versus PA grade 0–1. Other independent prognostic factors for OS included neutrophil count > 7 G/L (HR = 2.71, p = 0.010) and ypN+ (HR = 10.35, p < 0.001). RBT had no significant impact.

Conclusion

This retrospective analysis demonstrated that PA grade > 1 negatively impacts overall survival, independent of other prognostic factors, in patients with MIBC treated with NAC. However, it remains necessary to determine whether — and how — optimizing hemoglobin levels before cystectomy could improve outcomes.